Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : The companies are collaborating to apply Artificial Intelligence (AI) technology and advanced imaging strategies to further the development of AR-67, a third generation Camptothecin, in patients with recurrent glioblastoma multiforme (reGBM).
Brand Name : AR-67
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 03, 2021
Lead Product(s) : Berubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : CNS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin
Details : IAG, a leading medical imaging company, will work closely with CNS during the Berubicin clinical trials to provide critical imaging services, its proprietary platform DYNAMIKA and imaging data analysis.
Brand Name : RTA 744
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 24, 2020
Lead Product(s) : Berubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : CNS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
